Meeting
2023 ASCO Annual Meeting
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
Authors
Christian Frederick Meyer
Johns Hopkins Hospital, Baltimore, MD
Christian Frederick Meyer , Matthew Ingham , James S Hu , Giles Francis Whalen , Jacob Stephen Thomas , Anthony B. El-Khoueiry , Diana L. Hanna , Luis H. Camacho , Anthony J. Olszanski , Nilofer Saba Azad , Ian B. Walters , Lewis H. Bender , Lillian L. Siu , Albiruni Ryan Abdul Razak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
03058289
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11568)
DOI
10.1200/JCO.2023.41.16_suppl.11568
Abstract #
11568
Poster Bd #
502
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].](https://d201v5jt9ylckg.cloudfront.net/288/14408/208006/208006_A1471_poster_pv.jpg)
INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].
First Author: Matthew Ingham
Poster
2021 ASCO Annual Meeting
Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.
First Author: Matthew Ingham
Poster
2021 ASCO Annual Meeting
![A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.](https://d201v5jt9ylckg.cloudfront.net/273/13618/196128/196128_A711_poster_pv.jpg)
A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.
First Author: Anthony B. El-Khoueiry
Poster
2023 ASCO Annual Meeting
High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.
First Author: Julie Williamson